ENDRA Life Sciences Inc. (NASDAQ:NDRA) Short Interest Down 96.7% in October

ENDRA Life Sciences Inc. (NASDAQ:NDRA) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 24,000 shares, a decline of 96.7% from the October 15th total of 717,700 shares. Based on an average trading volume of 316,200 shares, the days-to-cover ratio is presently 0.1 days. Currently, 4.6% of the company’s stock are sold short.

ENDRA Life Sciences Trading Down 5.3 %

NDRA stock traded down $0.32 during mid-day trading on Wednesday, hitting $5.73. 52,372 shares of the company were exchanged, compared to its average volume of 98,000. ENDRA Life Sciences has a twelve month low of $5.23 and a twelve month high of $4,882.50. The firm has a fifty day simple moving average of $8.15 and a 200 day simple moving average of $7,616.00. The company has a market capitalization of $2.83 million, a PE ratio of 0.00 and a beta of 0.74.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($140.00) EPS for the quarter, missing analysts’ consensus estimates of ($122.50) by ($17.50). As a group, sell-side analysts anticipate that ENDRA Life Sciences will post -387.41 earnings per share for the current year.

About ENDRA Life Sciences

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.